-->

About us

About the FLCCC Alliance

The FLCCC Alliance – On a Mission to Save Thousands & Slow the Pandemic (A brief self-introduction; Jan 19, 2021)

The FLCCC Alliance was organized in March, 2020 by a group of highly published, world renowned Critical Care physician/scholars – with the academic support of allied physicians from around the world – to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol – introduced in March, 2020, has saved tens of thousands of patients who were critically ill with COVID-19. Now, the FLCCC’s new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with ivermectin has been released – and is a potential solution to the global pandemic.

The Front Line COVID-19 Critical Care Alliance was initially formed as a working group under “emergency” conditions of the early COVID-19 pandemic in response to multiple early reports of COVID patients with an inexplicably high need for prolonged mechanical ventilation and an excessive mortality associated with the prevailing “supportive care only” recommendations disseminated by the majority of national and international health care organizations.

As a group of highly published leaders in critical care with expertise in therapies directed at severe infections – in particular “HAT” therapy first developed by Dr. Paul Marik for the treatment of bacterial sepsis – and along with published high patient survival rates from our centers, we were contacted by equally concerned and motivated colleagues from other specialties.

With the increasing publications in addition to our rapidly accumulating personal clinical experiences and investigations into the pathophysiology of COVID-19 patients, we formulated the  MATH+ Hospital Treatment Protocol in March 2020. On August 5, 2020, we published our findings in the rationale paper  Scientific Review of COVID-19 and MATH+.

In October 2020, the FLCCC Alliance identified, based on a review of the recent and rapidly emerging clinical trials evidence, that ivermectin, an anti-parasitic medicine, has highly potent real-world, anti-viral, and anti-inflammatory properties against SARS-CoV-2 and COVID-19. This conclusion is based not only from multiple in-vitro and animal models, but from numerous clinical trials from centers and countries around the world showing repeated, consistent, large magnitude improvements in clinical outcomes when ivermectin is used not only as a prophylactic agent but also in mild, moderate, and even severe disease states. Further, data from large “natural experiments” that appear to have occurred when various regional health ministries and govern­mental authorities within South American countries, initiated “ivermectin distribution” campaigns which then led to temporally associated decreases in case counts and case fatality rates.

Based on these findings, the FLCCC team has developed the  I-MASK+ protocol for prophylaxis and at home treatment of early stage disease. You can read our  Scientific Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19.

A more detailed story of the inception and evolution of the FLCCC Alliance you’ll find in the  The FLCCC Alliance Story.

Mission Statement and Objectives of the FLCCC Alliance

Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic, the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease.

We are dedicated to

  • Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiologic studies.
  • Developing effective treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.
  • Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevention strategies to the use of our combination-based therapy protocols in both early-stage (I-MASK+) and hospitalized patients (MATH+).
  • Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strate­gies designed to optimize health.
  • Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.
  • Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19.

We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public.

Our funding needs are

  • To conduct a public awareness campaign to promote disease prevention and early treatment by hiring media and public relations professionals to engage and optimize the use of radio, print, television, and social media to gain awareness of, and interest in, our medical insights and effective treatment protocols, in particular the recently proven prophylaxis and early treatment protocol called I-MASK+.
  • To fund website design professionals to keep our internet presence and information portals current, up-to-date, user friendly, and informative with the latest medical information and treatment recommendations.
  • To support staff able to lobby government and other major healthcare agencies with the aim of both having those agencies validate the evidence in support of our identified therapies and consequently adopt them on a large scale, ideally forming a new standard of care for COVID-19.

 Download our Mission Statement and Objectives

Please go to our  donations page if you would like to support our education of medical professionals and the public in safe and effective ways to prevent and treat COVID-19.